AtriCure (ATRC) vs Heartflow (HTFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AtriCure (ATRC) has outperformed Heartflow (HTFL) over the past year, gaining 53.1% versus a gain of 51.3%. Heartflow is the larger company by market cap ($4.10 billion vs $2.82 billion), about 1.5 times the size. On valuation, Heartflow trades at a lower trailing P/E (69.7x vs 178.7x for AtriCure).
AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -66.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | HTFL |
|---|---|---|
| Share price | $55.39 | $46.69 |
| Market cap | $2.82B | $4.10B |
| 1-day change | +2.37% | +4.62% |
| YTD return | +40.02% | +60.17% |
| 1-year return | +53.14% | +51.35% |
| 5-year return | -22.00% | — |
| P/E ratio (TTM) | 178.68 | 69.69 |
| Forward P/E | 122.12 | — |
| EPS (TTM) | $0.31 | $0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $176.03M |
| Revenue growth (YoY) | +14.88% | +39.92% |
| Net income (latest FY) | $-11.45M | $-116.79M |
| Gross margin | 74.98% | 76.80% |
| Operating margin | -1.77% | -36.39% |
| Net margin | -2.14% | -66.35% |
| 52-week high | $66.02 | $60.66 |
| 52-week low | $25.36 | $20.13 |
| Distance from 52-week high | -16.10% | -23.02% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +17.15% | +39.22% |
| Average volume | 1.04M | 1.84M |
| Shares outstanding | 50.92M | 87.89M |
| Employees | 1,350 | 843 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AtriCure trades at a higher earnings multiple (178.7x vs 69.7x trailing P/E).
- AtriCure is more profitable, keeping -2.1 cents of every revenue dollar as net income versus -66.3 cents for Heartflow.
- Heartflow grew revenue faster in its latest fiscal year (+39.92% vs +14.88%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Heartflow
HTFL stock →HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries.
Health Care · Medical/Dental Instruments · 843 employees
ATRC vs HTFL FAQ
Which is bigger, AtriCure or Heartflow?
Heartflow (HTFL) is larger, with a market capitalization of $4.10B compared with $2.82B for AtriCure (ATRC).
Which stock has performed better over the past year, ATRC or HTFL?
ATRC returned +53.14% over the past 12 months, compared with +51.35% for HTFL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATRC or HTFL?
HTFL has the lower trailing P/E at 69.7, versus 178.7 for ATRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are AtriCure and Heartflow in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.